Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Clinical Updates

  • Home
  • Clinical Updates
Uncovering the Hepatocyte CEBPA-ORM1 Axis: A Novel Regulatory Pathway and Biomarker in Alcohol-Associated Liver Disease
Posted inClinical Updates Gastroenterology news

Uncovering the Hepatocyte CEBPA-ORM1 Axis: A Novel Regulatory Pathway and Biomarker in Alcohol-Associated Liver Disease

Posted by MedXY By MedXY 03/10/2026
This review synthesizes recent findings identifying the CEBPA-ORM1 axis as a critical suppressor of alcohol-associated liver disease, highlighting its potential as both a therapeutic target and a diagnostic biomarker for disease staging.
Read More
Pioneering FDA Approvals in Women’s Health: Transforming Care in 2025
Posted innews OB/GYN & Women's Health

Pioneering FDA Approvals in Women’s Health: Transforming Care in 2025

Posted by MedXY By MedXY 07/29/2025
Exploring groundbreaking FDA approvals in women's health, including new treatments for UTIs, at-home STI and cervical cancer tests, and AI-driven fetal anomaly detection.
Read More
  • Why Prevalence Is Rising Differently in Parkinson Disease, Multiple Sclerosis, and Motor Neuron Diseases
  • Mechanical Thrombectomy and Final Infarct Volume in Medium or Distal Vessel Occlusion Stroke: A Post Hoc Analysis of a Randomized Clinical Trial
  • High-Intensity Interval Exercise in Type 1 Diabetes: Stronger Protection Against Exercise-Related Glycaemic Decline in the Postabsorptive Than Postprandial State
  • Biochemical Control Is Not Enough: Why Acromegaly Still Carries Major Quality-of-Life and Treatment Burden
  • Early 15% Weight Loss After Type 2 Diabetes Diagnosis Linked to Lower Complication Risk
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in